DISCOUNT ZERTIFIKAT - VERTEX PHARMACEUTICALS | Real-time Bid/Ask 04:02:42 31/05/2024 pm IST | ||
| 402.1 EUR / 406.19 EUR | +0.39% |
|
| Current month | +8.71% | ||
| 1 month | +8.71% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 31/24/31 | 404.1 | +0.39% |
| 30/24/30 | 402.6 | -0.62% |
| 29/24/29 | 405.1 | -0.05% |
| 28/24/28 | 405.3 | -1.20% |
| 27/24/27 | 410.2 | +0.22% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 11:34 am IST
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | ME7WVA |
| ISIN | DE000ME7WVA4 |
| Date issued | 30/01/2024 |
| Maturity | 21/06/2024 (22 Days) |
| Parity | 1 : 1 |
| Emission price | 383.2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 410.2 € |
|---|---|
| Lowest since issue | 363.9 € |
| Spread | 4.11 € |
| Spread % | 1.01% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
443
USD
Average target price
462.8
USD
Spread / Average Target
+4.46%
- Stock Market
- Certificates
- Certificat
